Shou J, Ma J, Wang X, Li X, Chen S, Kang B
Adv Sci (Weinh). 2024; 12(2):e2406191.
PMID: 39558866
PMC: 11727260.
DOI: 10.1002/advs.202406191.
Vu H, Nguyen V, Ikenaga H, Matsubara T
Biomedicines. 2024; 12(8).
PMID: 39200340
PMC: 11351628.
DOI: 10.3390/biomedicines12081876.
Zyoud S, Hegazi O, Alalalmeh S, Shakhshir M, Abushamma F, Khilfeh S
World J Hepatol. 2024; 16(6):951-965.
PMID: 38948442
PMC: 11212647.
DOI: 10.4254/wjh.v16.i6.951.
Heintz M, Haws L, Klaunig J, Cullen J, Thompson C
Toxicol Sci. 2023; 192(1):15-29.
PMID: 36629480
PMC: 10025879.
DOI: 10.1093/toxsci/kfad004.
Theys C, Lauwers D, Perez-Novo C, Vanden Berghe W
Biomedicines. 2022; 10(12).
PMID: 36551797
PMC: 9775974.
DOI: 10.3390/biomedicines10123041.
Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease.
Fu Y, Zhou Y, Shen L, Li X, Zhang H, Cui Y
Front Pharmacol. 2022; 13:973366.
PMID: 36408234
PMC: 9666875.
DOI: 10.3389/fphar.2022.973366.
PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH).
Todisco S, Santarsiero A, Convertini P, De Stefano G, Gilio M, Iacobazzi V
Biology (Basel). 2022; 11(5).
PMID: 35625520
PMC: 9138523.
DOI: 10.3390/biology11050792.
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients.
Lange N, Graf V, Caussy C, Dufour J
Int J Mol Sci. 2022; 23(8).
PMID: 35457120
PMC: 9028563.
DOI: 10.3390/ijms23084305.
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates.
Prikhodko V, Bezborodkina N, Okovityi S
Biomedicines. 2022; 10(2).
PMID: 35203484
PMC: 8869100.
DOI: 10.3390/biomedicines10020274.
Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice.
Duan J, Wang Z, Duan R, Yang C, Zhao R, Feng Q
Hepatology. 2021; 75(1):140-153.
PMID: 34510514
PMC: 8688219.
DOI: 10.1002/hep.32148.
Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention.
Orabi D, Berger N, Brown J
Cancers (Basel). 2021; 13(14).
PMID: 34298687
PMC: 8307710.
DOI: 10.3390/cancers13143473.
Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease.
Thibaut R, Gage M, Pineda-Torra I, Chabrier G, Venteclef N, Alzaid F
FEBS J. 2021; 289(11):3024-3057.
PMID: 33860630
PMC: 9290065.
DOI: 10.1111/febs.15877.
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.
Francque S, Szabo G, Abdelmalek M, Byrne C, Cusi K, Dufour J
Nat Rev Gastroenterol Hepatol. 2020; 18(1):24-39.
PMID: 33093663
DOI: 10.1038/s41575-020-00366-5.
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.
Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W
Cells. 2020; 9(7).
PMID: 32650421
PMC: 7408116.
DOI: 10.3390/cells9071638.
Current and Future Treatments in the Fight Against Non-Alcoholic Fatty Liver Disease.
Smeuninx B, Boslem E, Febbraio M
Cancers (Basel). 2020; 12(7).
PMID: 32605253
PMC: 7407591.
DOI: 10.3390/cancers12071714.
The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
Kumar D, Caffrey R, Marioneaux J, Santhekadur P, Bhat M, Alonso C
Sci Rep. 2020; 10(1):9330.
PMID: 32518275
PMC: 7283326.
DOI: 10.1038/s41598-020-66458-z.
Hepatic Lipid Catabolism via PPARα-Lysosomal Crosstalk.
Sinha R, Rajak S, Singh B, Yen P
Int J Mol Sci. 2020; 21(7).
PMID: 32244266
PMC: 7170715.
DOI: 10.3390/ijms21072391.
Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J, Schlerman F, Akare S, Wang J, McMahon J, Zhan Y
PLoS One. 2020; 14(12):e0226854.
PMID: 31891606
PMC: 6938381.
DOI: 10.1371/journal.pone.0226854.
Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.
Choudhary N, Kumar N, Duseja A
J Clin Exp Hepatol. 2020; 9(6):731-739.
PMID: 31889755
PMC: 6926194.
DOI: 10.1016/j.jceh.2019.06.004.
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Boeckmans J, Natale A, Rombaut M, Buyl K, Rogiers V, Kock J
Cells. 2019; 9(1).
PMID: 31877771
PMC: 7016963.
DOI: 10.3390/cells9010037.
